Sassine leaves Visiomed

By Renate Krelle
Monday, 07 February, 2005

WA biotech Visiomed (ASX:VSG) has replaced retiring CEO Saliba Sassine with William Dolphin, formerly of New Zealand's SpectraNet and patient monitoring equipment company, SonaMed.

Dolphin, who is to take control in April, will be responsible for moving Visiomed's FDA-cleared asthma device, the Funhaler, into commercial production.

The change is one of several to have occurred at CEO level among Australian biotechs this year.

AusBiotech partners with Tenmile

Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...

Australian CDC issues update in wake of Ebola outbreak

After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...

Australia announces $7.2m diphtheria outbreak response package

To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...

Content from other channels on our network

Siemens expands Queensland manufacturing facility

Customer demand exceeding capacity for Alpha HPA

Curtin University project to research sustainable gallium processing

How to extend the life of your motor bearings

Mars Petcare Wodonga expansion boosts manufacturing output

Siemens expands Fusesaver manufacturing facility

BESS project provides long-duration battery for NSW

Lessons in long-distance telemetry

GECA and ACOR launch national standard for recycling

Antibiotics in wastewater may contribute to antimicrobial resistance

Unify risk and compliance to protect patients.

Australian health care's burnout prescription

"Fake podiatrist" jailed after hundreds of consultations with vulnerable patients

Unlocking the potential of our nursing workforce

National Model for Clinical Governance now available